FDA IND-Stage Oncology Platform Positioned Ahead of Key Clinical Milestones
RAM Pharmaceuticals is advancing a patented direct-to-lesion dry-powder delivery process supporting oncology development and near-term dental commercialization opportunities.
For accredited and strategic investor inquiries only.
A Platform Built for Direct-to-Source Delivery
RAM Pharmaceuticals is developing a patented direct-to-lesion dry-powder delivery process designed to place medication directly at the source of oral lesions.
The platform is being advanced through two focused divisions: RAMtherapeutics for oncology supportive care and RAMdental for dental commercialization.
This dual-market strategy is intended to support long-term clinical value creation while building near-term commercial traction.
Addressing a Serious Unmet Need in Cancer Supportive Care
Radiation- and chemotherapy-induced oral mucositis can cause severe pain, difficulty eating, difficulty speaking, treatment interruption, weight loss, and reduced quality of life for cancer patients.
RAMtherapeutics is focused on advancing Triamdocaine as an investigational therapy for oral mucositis through an active FDA IND pathway.
- Severe patient burden
- Limited effective treatment options
- Potential clinical value inflection through Phase 2 evaluation
Near-Term Commercial Strategy Through RAMdental
RAMdental provides RAM Pharmaceuticals with a near-term commercial pathway through Acyclonine MUM, a 503B dental product intended for professional dental use.
This strategy gives RAM a differentiated position: a clinical-stage oncology opportunity supported by a dental commercialization pathway.
- Provider-focused dental channel
- Existing 503B pathway
- Potential recurring product demand
- Revenue strategy designed to support oncology advancemend
Why Now?
Investor Relations Access
RAM Pharmaceuticals is currently engaging a limited group of accredited and strategic investors pursuant to Rule 506(c).
Qualified investors may request company materials, schedule management discussions, and review additional information through RAM’s investor relations process.
RAM Pharmaceuticals is currently conducting offerings pursuant to applicable securities exemptions, including Rule 506(c) under Regulation D. Investment opportunities are available only to verified accredited investors.
Nothing contained on this website constitutes an offer to sell or a solicitation of an offer to buy securities. Any offering will be made only through appropriate offering documents and in accordance with applicable securities laws.